

CERTIFICATE OF MAILING

I hereby certify that this paper and every paper referred to therein as being enclosed is being deposited with the U.S. Postal Service as first class mail, postage prepaid, in an envelope addressed to: Commissioner of Patents & Trademarks, Washington, DC 20231,

on _____ (Date of Deposit)

Date _____ Name _____

File No. 1010/16104-US4

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): HOWARD L. WEINER et al.

Serial No.: 08/279,275

Examiner: P. Achutamurthy

Filed: July 22, 1994

Group Art Unit: 1816

For: TREATMENT OF AUTOIMMUNE DISEASES BY ORAL ADMINISTRATION OF AUTOANTIGENS

RECEIVED

OCT 22 1996

DECLARATION OF PROF. DR. KLAUS TOYKA MATRIX CUSTOMER SERVICE CENTER

KLAUS V. TOYKA hereby declares:

1. I am a University Professor and Chairman in the Department of Neurology at the Bayerische Julius-Maximilians-Universität in Würzburg, Germany. My specialty is neuroimmunology. I have been involved with research and treatment of neurological autoimmune disorders including multiple sclerosis, and myasthenia gravis, polyneuritis and polymyositis for more than 20 years. I am also familiar with the literature in the field of neurological autoimmune disorders and am an author of more than 160 publications on the subject of autoimmunity. My qualifications are set forth in greater detail in my curriculum vitae attached as Exhibit 1.

2. I am not a co-inventor of the above identified application and I am not employed by the owner of the application. At the request of the applicant, I have reviewed the Campbell *et al.*, Whitacre *et al.*, and Nagler-Anderson *et al.* references which I understand have been applied to reject the claims in this application. I have also reviewed the results of clinical studies conducted by the inventors and described in the article attached as Exhibit 2.

3. It is my opinion that the oral tolerization of human patients described in this patent application and in the human trials described in annexed Exhibit 2 represents a meaningful and unexpected advance in the study of autoimmune diseases and in the treatment of MS. It is my understanding that the human trials I reviewed were conducted according to teachings in the patent application. These data show that myelin of which a major constituent is myelin basic protein (MBP) was orally administered to patients afflicted with the relapsing/remitting form of multiple sclerosis (MS). Of the patients receiving placebo in the study 12 out of 15 had MS attacks. Of the patients receiving oral MBP in the study, only 6 out of 15 suffered attacks of MS. Furthermore, there was a decrease in MBP reactive cells in the subjects fed myelin as compared to the placebo fed subjects and there was no evidence of toxicity or worsening of disease in the MBP-fed patients.

4. In my opinion these oral tolerization method results in humans were not suggested or described by the literature prior to 1987, when I understand the patent applica-

tion was filed. My opinion is explained in more detail below, and is based on my knowledge of autoimmune diseases and their treatment, including particularly multiple sclerosis, and on my review of the specification and other materials described herein.

5. It is my opinion that a person of ordinary skill in the field of autoimmune disease would find that the present invention is new and nonobvious, in comparison to the prior art Whitacre, Nagler-Anderson and Campbell.

6. The Whitacre Abstract reports on administration of MBP to animals which were subsequently immunized with MBP to induce experimental autoimmune encephalitis (EAE). In my opinion, those skilled in the art of neuroimmunology and autoimmune diseases, in 1986 or 1987, would not have sought to orally administer MBP to humans based on the teachings in the Whitacre reference, alone or considered together with the Campbell and Nagler-Anderson references. It is also my opinion that skilled practitioners, including researchers, clinicians and physicians, would not have extrapolated from the animal data of the Whitacre Abstract or the other references to the treatment of MS in humans, and would not have expected MBP to be suitably or successfully applied to human MS patients. The reasons for this are as follows.

7. In 1986/1987, those skilled in the fields of neuroimmunology and autoimmune diseases understood that there was a strong possibility that oral administration of myelin basic protein (MBP) to an individual afflicted with multiple sclerosis could actually worsen the patient's condition. This could occur

because it was thought that individuals afflicted with multiple sclerosis would likely already have been sensitized to the autoantigen responsible for the disease. Although it was not known for certain the MBP was the autoantigen responsible for MS, this was suspected to be the case. Hence, those skilled in the field did not turn to MBP as a treatment option. On the contrary, it was feared that oral administration of MBP could result in a heightened autoimmune reaction that would be seriously detrimental to patients. In short, it was believed that MBP could make the patient worse, not better. There was no expectation that MBP would work to alleviate MS in humans, despite reported animal experiments, such as those of Whitacre.

8. As early as 1977 I discussed the issue of oral tolerization with several colleagues in North America and Europe. Our discussions at that time related to the use of oral tolerization for possible treatment of myasthenia gravis, an autoimmune disease for which the responsible autoantigen was already known at the time. My colleagues and I hesitated to use oral tolerization for treatment of myasthenia gravis because we were afraid that such treatment would worsen the disease rather than treating it. Accordingly, I never made any use of oral tolerization for the treatment of myasthenia gravis, nor to my knowledge did any of the individuals with whom I had discussed the matter.

9. In the mid-1980s, I and many of my colleagues discussed the possible use of oral tolerization in other neuroimmunologic disorders including multiple sclerosis and polyneuritis. In both diseases, the antigen to which the immune

response is mounted was unknown. The various putative antigens, including myelin basic protein and other molecules, were not used by me or other experts in this field to treat these disorders because of our fear that such treatment would worsen the diseases in question. The work with animal models, such as the brief report in Whitacre, did not encourage me or my colleagues to apply oral tolerance to humans as a way to treat autoimmune diseases. We did not expect that chronic autoimmune diseases could be successfully treated by oral tolerance, or that human MS patients in particular could be treated by oral administration of MBP.

10. Oral administration of myelin basic protein also was not used to treat multiple sclerosis in 1986 or 1987, because at that time it was known that patients afflicted with multiple sclerosis have defects in their ability to generate immune suppression. Thus, even if an autoantigen was orally administered to such patients, the autoantigen may not have triggered the suppression response necessary to dampen the subject's autoimmune response. Because of this defect in suppression, such administration ran the risk of further sensitization, which would not treat the disease and could aggravate the patient's condition.

11. The teachings in the Campbell, Whitacre and Nagler-Anderson references would not have led those skilled in the field of autoimmune disease to experiment with the use of myelin basic protein in the treatment of multiple sclerosis. First, there was a fear of worsening the disease, as discussed

above. Second, there are significant differences between the animal models disclosed in Whitacre and Nagler-Anderson and human patients that are afflicted with an autoimmune disease, and particularly multiple sclerosis.

12. In the animal model, laboratory rats are fed the same autoantigen that is used to experimentally induce acute allergic encephalitis (EAE). Although experimental autoimmune EAE is somewhat akin to MS, and is useful for research, it is not the same disease in the same host and was not expected to behave in the same way. The same can be said of collagen-induced arthritis (CIA) a rodent model for rheumatoid arthritis (RA). Additionally, the animal model is based on the prevention or suppression of an acute condition that is artificially induced in the animal. In other words, unlike the human patient, the animal (in Whitacre and Nagler-Anderson) is not suffering from a chronic disease, has not been sensitized prior to administration of the autoantigen, and does not have an abnormal, compromised, or suppressed immune system associated with chronic autoimmune disease. This is quite different from a human patient afflicted with a chronic autoimmune condition such as multiple sclerosis. Here, the patient has been sensitized to the autoantigen over a long period of time -- even before the clinical manifestation of the disease -- and is afflicted with a chronic condition which is not easily reversed.¹

¹ Nagler-Anderson, which reports that feeding collagen after immunization is ineffective in suppressing collagen-induced arthritis, supports the view that oral tolerization would not be
(continued...)

13. Under the circumstances, the suppression or prevention of an artificially induced surrogate disease in Lewis rats (EAE) was not readily transferable to the treatment of a chronic and therapy-resistant disease in humans (MS). Given the state of the art and the literature in 1986/87, there was no expectation that oral administration of MBP could be successfully used to treat MS in humans.

14. It should also be noted that the animal model employed by Whitacre et al. and similar models employed prior to 1987, did not address concerns about immunosuppression and sensitivity in human patients suffering from a persistent chronic disease. The models are directed to an acute autoimmune episode induced in laboratory animals, where sensitivity and immunosuppression of the kind observed in humans did not arise. Thus, the animal model and animal results were not readily transferable to humans. Moreover, the animal model had no bearing on the very real concern that oral administration of an autoantigen to humans (such as MBP for MS) would do more harm than good. In my opinion, a person of ordinary skill at the pertinent time would not have applied the Whitacre animal model to humans, because of the very real obstacles to successful treatment of humans which are not reflected in the animal model or the Abstract. These obstacles were and are well known to practitioners. In fact, it has been my personal experience that practitioners with knowledge

¹(...continued)
effective in humans. Patients who develop autoimmune diseases, such as MS and RA, in fact suffer from an immune disorder long before clinical manifestation of the disease.

of the EAE animal model actually did not apply or transfer that model to humans. To the best of my knowledge, only the inventors of this application did so, despite the serious obstacles at the time.

15. In my opinion, results of animal experiments based on oral administration of MBP were not seen as transferable to humans because of significant limitations of the animal models. The risk of aggravated oral sensitization and immunosuppression in humans outweighed any desire to try oral MBP in humans. Thus, serious obstacles to the successful oral administration of MBP to humans were present, because of the fear that patients could actually be made worse by such treatment.

16. The Whitacre Abstract states that the results described "suggest that oral administration of MBP induces a state of antigen-specific unresponsiveness, which could be of value in establishing therapeutic protocols or multiple sclerosis." In my opinion, this was not an indication to skilled practitioners that oral administration of MBP can be successfully applied to humans afflicted with MS. This is so for the reasons given above, and in addition because the autoantigen for MS was not known. (MBP is a known autoantigen for EAE in rats, but was a suspected autoantigen in human MS.) This is another important difference between the animal model and human MS, which makes the invention in the application unexpectedly beneficial to patients. Since the autoantigen for MS was unknown, a person of ordinary skill in the field would not have taken the Abstract as any indication of a successful human therapy. Moreover, discussion

of future avenues for research are routine in abstracts of this kind, as is the hope that animal data might lead to more fruitful research in humans. Such statements, in my opinion, and in the context of the state of the art in autoimmune diseases in 1987, do not mean that the human therapy of the application is derivable from the Abstract. In my opinion, the successful oral use of MBP for MS patients according to the present application, and as demonstrated by clinical studies, was not predictable from the Abstract with any reasonable expectation of success, and provides a favorable therapeutic benefit.

17. The publication by Campbell reports on 64 human subjects afflicted with multiple sclerosis who were treated parenterally with human MBP for the stated purpose of testing it as a therapy in multiple sclerosis. Human myelin containing MBP was obtained from human brain and administered by intramuscular injection. The Campbell study has long been recognized in the field as extremely poorly designed and poorly conducted. The sole assessment was subjective: questionnaires answered by the patients, a notoriously unreliable practice. Moreover, the authors admitted (at p. 13 right col. and again at p. 14 left col.) that the questionnaires varied in wording and content, and they realized that the information provided in one questionnaire was not comparable with that of other questionnaires for the same patient. According to the reference, none of the patients were examined or assessed directly by a qualified physician (the sole examinations were only to verify that no new disease entity had arisen: p. 14 right col.), and no objective grading system was

employed (such as the Expanded Disability Status Scale). No attempt was made to randomize the patients who received myelin therapy or those who received placebo. There was considerable variability among the subjects as to both age and condition. All these glaring weaknesses were apparent to those skilled in the field even in 1974. The authors themselves recognized some of the weaknesses of their approach (Comments, pp. 14-15).

18. Thus, the study design and conduct of the Campbell clinical trial were far below the standard of a controlled clinical trial that was accepted by me and those skilled in the art of neuroimmunology and multiple sclerosis in the 1980's. In 1987, this trial design would in my opinion not have passed Internal Review Boards and Ethics Committees because of the foregoing multiple draw backs.² The study provides no clear indication that the tested treatment was promising. The results of Campbell et al. were in fact disregarded by the multiple sclerosis research and clinical community. To the best of my knowledge, no one followed up this study not even with synthetic fragments of MBP (which Campbell et al. suggested and which would have been free of the danger of infection). It would take what we know today, after the work described in the present patent

² In addition, the authors knowingly took unreasonable and unethical risks in injecting patients with human myelin at a time when they knew not only about the danger of sensitization but also either knew or should have known about the high risk of infecting patients with infectious PRION material which is the putative agent of the deadly Creutzfeld-Jacob disease (known in 1974 as "slow viral disease"). Although this practice by the authors is not germane to the subject at hand, it is consistent with the poor quality of their research.


application and after the clinical work done by the Weiner group, to ascribe, post-hoc, any significance to the results reported by Campbell.

19. For the reasons outlined above, it is my opinion, based on my experience with autoimmune diseases, in the field of clinical immunology, and in treating patients with multiple sclerosis for more than 20 years, that those skilled in the art in 1986/87 would not have employed the teachings in the Whitacre Abstract or any other animal models regarding administration of MBP or another autoantigen to animals afflicted with EAE in trying to treat human patients afflicted with MS by administering to such patients MBP via the oral route. The teachings in the Campbell publication using MBP via the intramuscular route in patients with MS is to be criticized for the severe weaknesses in the study design, and the unconvincing clinical observations. Therefore, those skilled in the art in 1986/87 would not have employed the teachings by Campbell in combination with those of Whitacre and/or Nagler-Anderson for the treatment of multiple sclerosis, whatever the route of administration of the anti-gen.

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may

jeopardize the validity of the application or any patent issuing
thereon.

2 Oct 96
DATE


PROF. DR. KLAUS V. TOYKA

Prof. Dr. K. V. Toyka

CURRICULUM VITAE

15 April 1945	born in Biberach, Germany
1950 - 1964	Primary School and High School education (including the equivalent to Junior College)
1964 - 1970	Medical School education at the University of Munich Medical Doctorate Thesis in Endocrinology
1970	U.S. Examination for Foreign Medical Graduates
1971	Medical Licensure
1971 - 1974	Residency at the Munich University Hospitals in Internal Medicine and Pediatric Neurology
1974 - 1976	Clinical and Research Fellow in Neuromuscular Diseases at the Johns Hopkins Medical Institutions, Baltimore, USA
1976 - 1979	Residency in Neurology and since 1978 Lecturer (Junior Faculty) Dept. of Neurology, Technical University, Munich
1979 - 1981	Tenured Associate Professor of Neurology, University of Düsseldorf. Head of the Neuroimmunology and Neuromuscular Labs.
1981 - 1989	Professor and Vice-Chairman, Department of Neurology, University of Düsseldorf
1989 to present	Professor and Chairman, University of Würzburg
Memberships	New York Academy of Sciences (1976), American Academy of Neurology (1986), American Neurological Association (1988), International Society of Neuroimmunology (1988), German Societies of Neurology, Muscular Dystrophy, and Physiology (1978), European Neurological Society

Prof. Toyka 2

Honors and Awards

Award of the Myasthenia Gravis Foundation,
U.S.A.,
Heinrich-Pette-Award of the German
Neurological Society,
President, Advisory Board of the German
MS Society,
Honorary Corresponding Member, Belgian
Neurological Society,
Named Lectureships
Associate Editor and Member of the Editorial
Board of International Science Journals

ORIGINALARBEITEN IN ZEITSCHRIFTEN

1. **K.V. Toyka, C. Förster, M. Dorn (1974)**
Alopecia areata und EEG-Veränderungen.
Hautarzt 25: 558-560
2. **K.V. Toyka, G.E. Janka, H.U. Janka et al. (1975)**
Effect of intravenous diphenylhydantoin on glucose tolerance and insulin response in children.
Neuropädiatrie 6: 176-183
3. **D.B. Drachman, K.V. Toyka, E. Myer (1975)**
Prednisone in Duchenne muscular dystrophy.
Lancet II: 1409-1412
4. **K.V. Toyka, D.B. Drachman, A. Pestronk et al. (1975)**
Myasthenia gravis: passive transfer from man to mouse.
Science 190: 397-399
5. **D.B. Drachman, I. Kao, A. Pestronk, K.V. Toyka (1976)**
Myasthenia gravis as a receptor disorder.
Ann. N.Y. Acad. Sci. 274: 226-234
6. **K.V. Toyka, D.B. Drachman, A. Pestronk et al. (1976)**
Myasthenia gravis: übertragbarer "myasthenogener" Faktor im Serum von Patienten.
J. Neurol. 212: 271-280
7. **K.V. Toyka, E.T. Mayer, C. Förster (1977)**
Hydroanenzephalie versus Markporenzephalie.
Arch. Psychiat. Nervenkrht. 224: 27-38
8. **K.V. Toyka, D.B. Drachman, D.E. Griffin et al. (1977)**
Myasthenia gravis: study of humoral immune mechanisms by passive transfer to mice.
N. Engl. J. Med. 296: 125-131
9. **W.R. Leahy, K.V. Toyka, K.H. Fischbeck (1977)**
Brain abscess after esophageal dilatation.
Pediatrics 59: 300-301
10. **P.M. Karpf, C.H. Lücking, K.V. Toyka, S. Wibowa, W. Hengl (1977)**
Periartikuläre Ossifikationen nach schwerem Schädel-Hirntrauma.
Fortschr. Med. 95: 1606-1608
11. **K.V. Toyka, K.L. Birnberger, A.P. Anzil, C. Schlegel, U. Besinger, A. Struppner (1978)**
Myasthenia gravis: further electrophysiological and ultrastructural analysis of the transmission failure in the mouse passive transfer model.
J. Neurol. Neurosurg. Psychiat. 41: 746-753
12. **J. Dudel, K.L. Birnberger, K.V. Toyka, C. Schlegel, U. Besinger (1979)**
Effects of myasthenic immunoglobulins and of prednisolone on spontaneous miniature potentials in mouse diaphragms.
Exp. Neurol. 66: 365-380
13. **K.V. Toyka, T. Becker, A. Fateh-Moghadam, U. Besinger, G. Brehm, D. Neumeier, K. Heininger, K.L. Birnberger (1979)**
Die Bedeutung von Antikörpern gegen Acetylcholin-Rezeptoren für die Diagnostik der Myasthenia gravis.
Klin. Wochenschr. 937-942

14. D. Pongratz, J. Perwein, K. Koppenwallner, G. Hübner, **K.V. Toyka**, K.L. Birnberger (1979)
Wertigkeit der Skelettmuskelbiopsie bei der progressiven externen Ophthalmoplegie.
Klin. Wochenschr. 57: 779-788
15. W. Samtleben, U.A. Besinger, **K.V. Toyka**, A. Fateh-Moghadam, G. Brehm,
B. Gurland (1980)
Plasma-separation in myasthenia gravis: a new method of rapid plasma exchange.
Klin. Wochenschr. 58: 47-49
16. K. Heininger, A. Fateh-Moghadam, **K.V. Toyka**, U.A. Besinger, J. Witthöft (1980)
Significance of acetylcholine receptor antibody in the diagnosis and therapy monitoring
of myasthenia gravis.
La Ricerca Clin. Lab. 10: 255-258
17. **K.V. Toyka**, B. Löwenadler, K. Heininger, U.A. Besinger, K.L. Birnberger,
A. Fateh-Moghadam, E. Heilbronn (1980)
Passively transferred myasthenia gravis: protection of mouse endplates by Fab fragments from human
myasthenic IgG.
J. Neurol. Neurosurg. Psychiat. 43: 836-842
18. **K.V. Toyka**, R. Augspach, W. Paulus, B. Grabensee, D. Hein (1980)
Plasma exchange in the Guillain-Barre'-syndrome.
Ann. Neurol. 8: 205-206
19. U.A. Besinger, **K.V. Toyka**, K. Heininger, A. Fateh-Moghadam, F. Schumm,
P. Sandel, K.L. Birnberger (1981)
Long-term correlation of clinical course and acetylcholine receptor antibody in patients with
myasthenia gravis.
Ann. N.Y. Acad. Sci. 377: 812-815
20. B. Löwenadler, **K.V. Toyka**, K. Heininger, U.A. Besinger, E. Heilbronn (1981)
Protection of endplates by Fab fragments from human myasthenic IgG in the mouse transfer model.
Ann. N.Y. Acad. Sci. 377: 842-843
21. U.A. Besinger, **K.V. Toyka**, A.P. Anzil et al (1981)
Myeloma neuropathy: passive transfer from man to mouse.
Science 213: 1027-1030
22. **K.V. Toyka**, R. Augspach, H. Wiethölter et al (1982)
Plasma exchange in chronic inflammatory polyneuropathy: evidence suggestive of a pathogenic
humoral factor.
Muscle Nerve 5: 479-484
23. R. Hohlfeld, K. Heininger, **K.V. Toyka** (1982)
Myasthenia gravis - Autoimmunerkrankung mit Modellcharakter.
Int. Welt 5: 205-212
24. W. Hammerstein, W. Mortier, E.H. Noack, H. Frenzel, U.G. Liebert, **K.V. Toyka**
et al (1983)
Klinische, morphologische und biochemische Befunde beim Kearns-Sayre Syndrom.
Fortschr. Ophthalmol. 80: 193-200
25. R. Hohlfeld, A. Schwartz, U. Brocke, **K.V. Toyka** (1983)
Immunofluorescence analysis of CSF cells with monoclonal antibodies: the inflammatory
lymphoproliferative syndrome.
Klin. Wochenschr. 61: 933-934

26. U.A. Besinger, **K.V. Toyka**, M. Hömberg et al (1983)
Myasthenia gravis: long-term correlation of binding and bungarotoxin blocking antibodies against acetylcholine receptors with changes in disease severity.
Neurology (N.Y.) 33: 1316-1321
27. H. Grosse-Wilde, **K.V. Toyka**, U.A. Besinger et al (1983)
Zur Immungenetik der Myasthenia gravis: Bedeutung der HLA-Komplement- und Gm-Gensysteme für klinische und immunologische Parameter.
Dtsch. Med. Wochenschr. 108: 694-700
28. K. Heininger, M. Hendricks, H. Kolb, **K.V. Toyka** (1983)
Myasthenia gravis: Remission not induced by blocking anti-idiotype antibodies.
Muscle Nerve 6: 386-387
29. H.P. Hartung, **K.V. Toyka** (1983)
Tuftsin stimulates the release of oxygen radicals and thromboxane from macrophages.
Immunology Lett. 6: 1-6
30. H.P. Hartung, **K.V. Toyka** (1983)
Activation of macrophages by substance P: induction of oxidative bursts and thromboxane release.
Eur. J. Pharmacol. 89: 301-305
31. U. Trockel, J.M. Schröder, K.H. Reiners, **K.V. Toyka**, G. Goerz, H.-J. Freund (1983)
Multiple exercise related mononeuropathy with abdominal colic.
J. Neurol. Sci. 60: 431-442
32. H. Kolb, **K.V. Toyka** (1983)
Autoimmune tissue damage: humoral or cellular mechanisms?
Immunol. Today 4: 331-334
33. R. Hohlfeld, **K.V. Toyka**, K. Heininger et al (1984)
Autoimmune human T lymphocytes specific for acetylcholine receptor.
Nature 310: 244-246
34. R. Seitz, **K.V. Toyka**, W. Wechsler (1984)
Adult onset mixed myopathy with nemaline rods, minicores, and central cores.
J. Neurol. 231: 103-108
35. K. Heininger, U.G. Liebert, **K.V. Toyka**, F. Haneveld et al (1984)
Chronic inflammatory polyneuropathy: Reduction of nerve conduction velocities in monkeys by systemic passive transfer of immunoglobulin G.
J. Neurol. Sci. 66: 1-14
36. H.P. Hartung, **K.V. Toyka** (1984)
Augmentation of oxidative and arachidonate metabolism in macrophages by tuftsin (Thr-Lys-Pro-Arg).
Agents and Actions 15: 38-39
37. K. Heininger, C. Edler, **K.V. Toyka** (1984)
Â-Fetoprotein and neonatal transient myasthenia gravis.
Neurology (Cleveland) 34: 403-404
38. **K.V. Toyka** (1984)
Neurologische Indikation zur Plasmapherese.
Akt. Neurol. 11: 114-117
39. R. Hohlfeld, **K.V. Toyka**, K. Heininger, B. Gerhold (1985)
Myasthenia gravis: Reactivation of clinical disease and of autoimmune factors after discontinuation of azathioprine.
Ann. Neurol. 17: 238-242

40. G. Stoll, G. Schwendemann, K. Heininger, A. Steck, **K.V. Toyka** (1985)
Human monoclonal anti-MAG antibody and anti-Leu 7 recognize shared antigenic determinants in peripheral nerve and spinal cord.
J. Neurol. Neurosurg. Psychiat. 48: 635-638
41. H. Kolb, **K.V. Toyka** (1984)
Immunotherapy of autoimmune diseases: New concepts.
Immunol. Today 5: 307-308
42. R. Hohlfeld, I. Brüske-Hohlfeld, A. Schwartz, U. Brocke, **K.V. Toyka** (1984)
Analyse von Oberflächenmarkern auf Liquorzellen als Beitrag zur Differentialdiagnostik intrathekaler Lymphome.
Dtsch. Med. Wochenschr. 109: 1760-1762
43. H.P. Hartung, K. Wolters, **K.V. Toyka** (1984)
Binding of substance P to macrophages: stimulation of the release of proinflammatory and immunomodulating compounds.
Neuroscience Lett. Suppl. 18: 101
44. H.P. Hartung, K. Wolters, **K.V. Toyka** (1986)
Substance P: Binding properties and studies on cellular responses in guinea pig macrophages.
J. Immunol. 136: 3856-3863
45. K. Heininger, M. Hendricks, **K.V. Toyka** (1985)
Myasthenia gravis: A new semiselective procedure to remove acetylcholine receptor autoantibodies from plasma.
Plasma Therapy 6: 771-775
46. R. Hohlfeld, **K.V. Toyka** (1985)
Strategies for the modulation of neuroimmunological disease at the level of autoreactive T-lymphocytes.
J. Neuroimmunol. 9: 193-204
47. R. Hohlfeld, B. Conti-Tronconi, I. Kalies, J. Bertrams, **K.V. Toyka** (1985)
Genetic restriction of autoreactive acetylcholine-specific T-lymphocytes in myasthenia gravis.
J. Immunol. 35: 2393-2399
48. R.J. Seitz, K. Heininger, G. Schwendemann, **K.V. Toyka**, W. Wechsler (1985)
The mouse blood-brain barrier and blood-nerve barrier for IgG: A tracer study by use of the avidin-biotin system.
Acta Neuropathol. (Berl.) 68: 15-21
49. A.J. Steck, N. Murray, J.C. Justafre, C. Meier, **K.V. Toyka** et al (1985)
Passive transfer studies in demyelinating neuropathy with IgM monoclonal antibodies to myelin associated glycoprotein.
J. Neurol. Neurosurg. Psychiat. 48: 927-929
50. G. Stoll, K.H. Reiners, K. Heininger, G. Schwendemann, **K.V. Toyka** (1986)
Normal myelination of regenerating peripheral nerve sprouts despite circulating antibodies to galactocerebroside in rabbits.
Ann. Neurol. 19: 189-192
51. K. Heininger, G. Stoll, C. Linington, **K.V. Toyka**, H. Wekerle (1986)
Conduction failure and nerve conduction slowing in EAN induced by P2-specific T-cell lines.
Ann. Neurol. 19: 44-49

52. E. Gibbels, **K.V. Toyka**, H. Borberg (1986)
Plasmaaustauschbehandlung bei chronischen Polyneuritiden vom Typ Guillain-Barre. Erfahrungen mit 9 eigenen Fällen.
Nervenarzt 57: 129-139
53. R.J. Seitz, K. Heininger, G. Schwendemann, **K.V. Toyka** (1986)
Application of the avidin-biotin-system for post-embedding cytochemical demonstration of a biotin-labelled tracer.
J. Cytochem. Histochem. 34: 547-549
54. R. Sterz, R. Hohlfeld, K. Rajki, H. Kaul, K. Heininger, K. Peper, **K.V. Toyka** (1986)
Effector mechanisms in myasthenia gravis: end-plate function after passive transfer of IgG, Fab, and F(ab')²-hybrids.
Muscle Nerve 9: 306-312
55. U. Trockel, H.R. Scholte, **K.V. Toyka**, H.F.M. Busch, I.E.M. Luyt-Houwen, J.A. Berden (1986)
Myopathy with abnormal mitochondria, transient low electron transport capacity by the respiratory chain, and absence of energy transduction at sites 1 and 2 in vitro.
J. Neurol. Neurosurg. Psychiat. 49: 645-650
56. G. Stoll, G. Schwendemann, K. Heininger, W. Köhne, H.P. Hartung, R. Seitz, **K.V. Toyka** (1986)
Relation of clinical, serological, morphological and electrophysiological findings in galactocerebroside-induced experimental allergic neuritis.
J. Neurol. Neurosurg. Psychiat. 49: 258-264
57. R. Hohlfeld, I. Kalies, B. Kohleisen, K. Heininger, B. Conti-Tronconi, **K.V. Toyka** (1986)
Myasthenia gravis: stimulation of anti-receptor autoantibodies by autoreactive T-cell lines.
Neurology 36: 618-621
58. R. Hohlfeld, M. Michels, H. Tesch, A. Fahsbender, K. Heininger, B. Conti-Tronconi, **K.V. Toyka** (1986)
Epstein-Barr virus-transformed B cells can present acetylcholine receptor to autologous autoreactive T cells.
Immunology Lett. 12: 171-174
59. B. Schwartzkopff, H. Frenzel, B. Lösse, M. Borggrefe, **K.V. Toyka**, W. Hammerstein, R. Seitz, M. Deckert, G. Breithardt (1986)
Herzbeteiligung bei progressiver exzenter Ophthalmoplegie (Kearns-Sayre-Syndrom): elektrophysiologische, hämodynamische und morphologische Befunde.
Z. Kardiol. 75: 161-169
60. J. Bell, L. Rassenti, S. Smoot, K. Smith, C. Newby, R. Hohlfeld, **K.V. Toyka**, H. McDevitt, L. Steinman (1986)
HLA-DQ beta-chain polymorphism linked to myasthenia gravis.
Lancet 1: 1058-1060
61. W. Hammerstein, R.J. Seitz, **K.V. Toyka**, B. Schwartzkopff (1986)
Netzhautdystrophie bei Mitochondriopathie
Ophthalmoplegie 83:320-324
62. **K.V. Toyka**, K. Heininger (1987)
Humoral factors in peripheral nerve disease.
Muscle Nerve 10: 222-232

63. K.V. Toyka, K. Heininger (1986)
Acetylcholin-Rezeptor-Antikörper in der Diagnostik der Myasthenia gravis. Untersuchung bei 406 gesicherten Fällen.
Dtsch. Med. Wochenschr. 111: 1435-1439
64. K. Heininger, K.V. Toyka, A. Gaczowski, H.P. Hartung, H. Borberg, B. Grabensee (1986)
Semi-selective removal of pathogenic factors in neurologic disease.
Plasma Therapy 7: 351-357
65. K. Heininger, H.P. Hartung, K.V. Toyka et al (1987)
Therapeutic plasma exchange in myasthenia gravis: semiselective absorption of anti-AChR autoantibodies with tryptophane-linked polyvinyl alcohol gels.
Ann. N.Y. Acad. Sci. 505: 898-900
66. R. Hohlfeld, K.V. Toyka, B. Conti-Tronconi et al (1987)
Anti-AChR lymphocyte lines from human myasthenic patients.
Ann. N.Y. Acad. Sci. 505: 27-38
67. H.P. Hartung, C. Schwenke, D. Bitter-Suermann, K.V. Toyka (1987)
Guillain-Barre' Syndrome: activated complement components C3a and C5a in cerebrospinal fluid.
Neurology 37: 1006-1009
68. R. Hohlfeld, K.V. Toyka, S. Tzartos, W. Carson, B. Conti-Tronconi (1987)
Epitopes on the alpha-subunit of torpedos acetylcholine receptor stimulate human T lymphocytes in myasthenia gravis.
Proc. Natl. Acad. Sci. (USA) 84: 5379-5383
69. R. Hohlfeld, M. Michels, K. Heininger, U. Besinger, K.V. Toyka (1987)
Azathioprine toxicity during long-term immunosuppression of generalized myasthenia gravis.
Neurology 38: 258-261
70. R. Hohlfeld, W. Johanns, A. Fahsbender, K.V. Toyka (1987)
A reliable method for immunocytochemical characterization of CSF cells.
Klin. Wochenschr. 65: 664-666
71. H.P. Hartung, K.V. Toyka (1987)
Phorbol diester TPA elicits prostaglandin E release from cultured rat astrocytes.
Brain Res. 417: 347-349
72. W. Hammerstein, R.J. Seitz, K.V. Toyka, B. Schwartzkopff (1987)
Retinal dystrophy and mitochondrial changes.
Adv. Biosci. 62: 75-81
73. H.P. Hartung, K.V. Toyka (1987)
Leukotriene production by cultured astroglial cells.
Brain Res. 435: 367-370
74. K. Heininger, B. Schäfer, H.P. Hartung, W. Fierz, C. Linington, K.V. Toyka (1988)
The role of macrophages in experimental allergic neuritis induced by a P2-specific T-cell line.
Ann. Neurol. 23: 326-331
75. H.P. Hartung, B. Schäfer, K. Heininger, K.V. Toyka (1988)
Suppression of experimental autoimmune neuritis by the oxygen radical scavengers superoxide dismutase and catalase.
Ann. Neurol. 23: 453-460

76. H.P. Hartung, B. Schäfer, W. Fierz, K. Heininger, **K.V. Toyka** (1987)
Ciclosporin A prevents P2-T cell line - mediated experimental autoimmune neuritis (AT-EAN).
Neurosci. Lett. 83: 195-200
77. H.P. Hartung, B. Schäfer, G. Stoll, K. Heininger, **K.V. Toyka** (1988)
The role of macrophages and eicosanoids in the pathogenesis of experimental allergic neuritis. Serial clinical, electrophysiological, and morphological observations.
Brain 111: 1039-1059
78. **K.V. Toyka** (1988)
Störungen der Rezeptorfunktion als pathogenetisches Prinzip bei der Myasthenia gravis.
Internist 29: 414-419
79. H.P. Hartung, K. Heininger, B. Schäfer, **K.V. Toyka** (1988)
Substance P and astrocytes-stimulation of the cyclooxygenase pathway of arachidonic acid metabolism.
FASEB Journal 2: 48-51
80. H.P. Hartung, **K.V. Toyka**, K. Heininger, B. Schäfer, W. Fierz (1988)
Immune mechanisms in inflammatory polyneuropathy.
Ann. N.Y. Acad. Sci. 540: 122-161
81. W. Fierz, K. Heininger, B. Schäfer, **K.V. Toyka**,
C. Linington, H. Lassmann (1988)
Synergism in the pathogenesis of EAE induced by an MBP-specific T cell line and monoclonal antibodies to galacto-cerebroside or to a myelin oligodendroglial glycoprotein.
Ann. N.Y. Acad. Sci. 540:
82. H.P. Hartung, K. Heininger, B. Schäfer, **K.V. Toyka** (1988)
Substance P stimulates release of arachidonic acid cyclooxygenation product from primary culture rat astrocytes.
Ann. N.Y. Acad. Sci. 540: 427-429
83. H.P. Hartung, B. Schäfer, W. Fierz, K. Heininger, T. Diamantstein, **K.V. Toyka** (1988)
Suppression of P2-T cell-line mediated experimental autoimmune neuritis by interleukin 2 - receptor blockade.
Ann. N.Y. Acad. Sci. 540: 563-565
84. K. Heininger, W. Fierz, B. Schäfer, H.P. Hartung, **K.V. Toyka** (1988)
Adoptive transfer of experimental autoimmune neuritis by interleukin 2 - receptor blockade.
Ann. N.Y. Acad. Sci. 540: 738-740
85. R. Hohlfeld, **K.V. Toyka**, L.L. Miner, S.L. Walgrave, B. Conti-Tronconi (1988)
Amphipathic segment of the nicotinic receptor alpha-subunit contains epitopes recognized by T-lymphocytes in myasthenia gravis.
J. Clin. Invest. 81: 657-660
86. R.J. Seitz, K. Reiners, F. Himmelmann, K. Heininger, H.P. Hartung, **K.V. Toyka** (1989)
The blood-nerve barrier for immunoglobulin G and complement: a sequential study with biotinylated tracers.
Muscle Nerve 12: 627-635
87. K. Heininger, W. Fierz, B. Schäfer, H.P. Hartung, P. Wehling, **K.V. Toyka** (1989)
Electrophysiological investigations in adoptively transferred experimental autoimmune encephalomyelitis in the Lewis rat.
Brain 112: 537-552
88. W. Steinke, G. Arendt, M. Mull, K.H. Reiners, **K.V. Toyka** (1989)
Good recovery after sublethal ethylene glycol intoxication. Serial EEG and CT- findings.
J. Neurol. 236: 170-173

89. M. Michels, R. Hohlfeld, H.P. Hartung, K. Heininger, U. Besinger, **K.V. Toyka** (1988)
Myasthenia gravis: Discontinuation of long-term azathioprine.
Ann. Neurol. 24: 798
90. H. Tesch, R. Hohlfeld, **K.V. Toyka** (1989)
Analysis of immunoglobulin and T cell receptor gene rearrangements in the thymus of myasthenia gravis patients.
J. Neuroimmunol. 21: 169-176
91. H.P. Hartung, B. Schäfer, T. Diamantstein, W. Fierz, K. Heininger, **K.V. Toyka** (1988)
Suppression of P2-T cell line mediated experimental autoimmune neuritis by interleukin 2 - receptor targeted monoclonal antibody ART 18.
Brain Res. 489: 120-127
92. H.P. Hartung, K. Heininger, **K.V. Toyka** (1988)
Neuromuskuläre Manifestationen der HIV-1 und HTLV-I-Infektionen.
Dtsch. Med. Wochenschr. 113: 1975-1981
93. **K.V. Toyka**, H.P. Hartung, B. Schäfer, K. Heininger, W. Fierz (1988)
Immune mechanisms in acute and chronic inflammatory polyneuropathies.
J. Neuroimmunol. 20: 277-281
94. H.P. Hartung, K. Heininger, **K.V. Toyka** (1988)
Primary rat astroglial cultures can generate leukotriene B4.
J. Neuroimmunol. 19: 237-243
95. H.P. Hartung, B. Schäfer, K. Heininger, **K.V. Toyka** (1989)
Recombinant interleukin-1 β stimulates eicosanoid production in rat primary culture astrocytes.
Brain Res. 489: 113-119
96. W. Steinke, G. Arendt, M. Mull, K. Reiners, and **K.V. Toyka** (1989)
Good recovery after sublethal ethylene glycol intoxication: serial EEG and CT findings.
J. Neurol. 236: 170-173
97. H.-P. Hartung, **K.V. Toyka** (1990)
Substance P, inflammation, and the immune system.
Internat. Rev. Immunolog. 4: 229-249
98. H.-P. Hartung, R.A.C. Hughes, W.A. Taylor, K. Heininger, K. Reiners, **K.V. Toyka** (1990)
T cell activation in the Guillain-Barré syndrome and in MS: elevated serum levels of soluble IL-2 receptors.
Neurology 48: 215-218
99. B. Schmidt, G. Stoll, B. Schäfer, H.P. Hartung, **K.V. Toyka** (1990)
Macrophages but not Schwann cells express Ia antigen in experimental autoimmune neuritis.
Ann. Neurol. 28: 70-77
100. H.-P. Hartung, B. Schäfer, P.H. van der Meide, W. Fierz, K. Heininger, **K.V. Toyka** (1990)
The role of interferon-gamma in the pathogenesis of experimental autoimmune disease of the peripheral nervous system.
Ann. Neurol. 27:247-257
101. H.-P. Hartung, **K.V. Toyka** (1990)
T cell and macrophage activation in EAN and the Guillain-Barré Syndrome.
Ann. Neurol. 27: S 57-S 63

102. B. Schmidt, G. Stoll, **K.V. Toyka**, H.-P. Hartung (1990)
Rat astrocytes express interferon-gamma immunoreactivity in normal optic nerve and after nerve transection.
Brain Res. 515: 347-350
103. H.-P. Hartung, K. Heininger, **K.V. Toyka** (1990)
Neue Aspekte zur Pathogenese und Therapie des Guillain Barré Syndroms und der chronischen Polyneuritis.
Nervenarzt 61: 197-207
104. M. Hennerici, **K. V. Toyka** (1990)
Paraneoplastic Syndrome am Nervensystem
Internist 31: 233 - 239
105. A. Palmowski, H. Reichmann, **K.V. Toyka** (1991)
Neurofibromatous Neuropathy.
Muscle & Nerve 14: 478-479
106. H.-P. Hartung, K. Reiners, B. Schmidt, G. Stoll, and **K.V. Toyka** (1991)
Serum interleukin-2 concentrations in Guillain-Barré syndrome and chronic idiopathic demyelinating polyradiculoneuropathy (CIDP). Comparison with other neurological diseases of presumed immunopathogenesis.
Ann. Neurol. 30: 48-53
107. E. Künstler, M. Warmuth-Metz, H.P. Hartung, P. Seeldrayers, and **K.V. Toyka** (1991)
Ist die Kernspintomographische Diagnostik bei MS sinnvoll?
Akt. Neurologie 18: 105-108
108. G. Stoll, B. Schmidt, S. Jander, **K.V. Toyka**, H.P. Hartung (1991)
Presence of the terminal complement complex (C5b-9) precedes myelin degradation in acute demyelination in the peripheral nervous system of the rat.
Ann. Neurol. 30: 147-155
109. **K.V. Toyka**, H.-P. Hartung (1991)
Immune mechanisms and therapeutic approaches in inflammatory disorders of the peripheral nervous system.
Ital. J. Neurol. Sci.: Suppl. 1: 11-17
110. S. Jung, H.J. Schluessener, **K.V. Toyka**, H.-P. Hartung (1991)
T cell vaccination does not induce resistance to experimental allergic neuritis.
J. Neuroimmunol. 35: 1-12
111. V. Hömberg, K. Reiners and **K.V. Toyka** (1992)
Reversible conduction block in human ischemic neuropathy after ergotamine abuse.
Muscle Nerve 15: 467-470
112. J. Zielasek, M. Tausch, **K.V. Toyka**, H.-P. Hartung (1992)
Production of nitrite by neonatal rat microglial cells./brain macrophages.
Cellular Immunol. 141: 111-120
113. S. Jung, H. J. Schluessener, T. Hüning, **K.V. Toyka**, H.-P. Hartung (1992)
Prevention and therapy of experimental autoimmune neuritis by an antibody against α/B T cell receptors.
J. Immunol. 148: 3768-3775
114. H.-P. Hartung, S. Jung, G. Stoll, J. Zielasek, B. Schmidt, J. J. Archelos, **K.V. Toyka**. (1992)
Inflammatory mediators in demyelinating disorders of the CNS and PNS.
J. Neuroimmunol. 40: 197-210

115. B.C.G. Schalke, B. Schmidt, K.V. Toyka, and H.-P. Hartung (1992)
Pravastatin-associated inflammatory myopathy.
N. Engl. J. Med. 327: 649 - 650.
116. J. Zielasek, J., S. Jung, B. Schmidt, G. Ritter, H.-P. Hartung, and K.V. Toyka (1993)
Effects of ganglioside administration on experimental autoimmune neuritis
induced by peripheral nerve myelin or P2-specific T cell lines.
J. Neuroimmunol. 43: 103 - 112
117. S. Jung, H.J. Schlüsener, K. V. Toyka, H.-P. Hartung (1993)
Modulation of EAE by vaccination with T cell receptor peptides: V β 8 T cell receptor peptide-specific
CD4 $^{+}$ lymphocytes lack direct immunoregulatory activity.
J. Neuroimmunol. 45: 15 - 22
118. J.J. Archelos, K. Roggenbuck, J. Schneider-Schaulies, C. Linington, K.V. Toyka, and H.-P. Hartung
(1993)
Production and characterization of monoclonal antibodies to the extracellular domain of P0.
J. Neurosci. Res. 35: 46-53
119. J. Zielasek, J. J. Archelos, K.V. Toyka, and H.-P. Hartung (1993)
Expression of ICAM-1 on rat microglial cells.
Neurosci. Letters 153: 136-139
120. J.J. Archelos, K. Roggenbuck, J. Schneider-Schaulies, K.V. Toyka, and
H.-P. Hartung (1993)
Detection and quantification of antibodies to the extracellular domain of P0 during experimental
allergic neuritis.
J. Neurol. Sci. 115: 197 - 205
121. G. Stoll, S. Jander, S. Jung, J. Archelos, T. Tamatani, M. Miyasaka, K.V. Toyka, and H.-P. Hartung
(1993)
Macrophages and endothelial cells express intercellular adhesion molecule-1 immune-mediated
demyelination but not in Wallerian degeneration of the rat peripheral nervous
system.
Lab. Invest. 68: 637 - 644
122. G. Stoll, S. Müller, B. Schmidt, P. van der Meide, S. Jung, K.V. Toyka,
and H.-P. Hartung (1993)
Localization of interferon-gamma and Ia-antigen in T cell line-mediated experimental autoimmune
encephalomyelitis.
Am. J. Pathol. 142: 1866 - 1875
123. H.-P. Hartung, J. Zielasek, K.V. Toyka (1993)
Reactive nitrogen intermediates: effector molecules of immune-mediated inflammatory nervous system
disorders. (Letter to the editor)
Ann. Neurol. 33: 422
124. B. Müller, K. Adelt, H. Reichmann, K.V. Toyka (1994)
Atraumatic needle reduces post-lumbar puncture syndrome
J. Neurol. 241: 376 - 380
125. A. Pohl-Koppe, C. Dahm, J.E. Kühn, J. Hamann, U. Fuhrmeister, M. Gabriel,
W. Grüninger, H. Metze, M. Ranke, K.V. Toyka, K. Wesseler, V. ter Meulen (1992)
Neue Aspekte in der Diagnostik der Herpes-simplex-Virusenzephalitis - Fallberichte und virologische
Befunde.
Der Nervenarzt 63: 495 - 502

126. H.-P. Hartung, **K.V. Toyka**
Guillain-Barré Syndrome Steroid Trial Group (1993) Double-blind trial of intravenous methyprednisolone in Guillain-Barré syndrome.
Lancet 341: 586 - 590
127. J.J. Archelos, S. Jung, M. Mäurer, H. Lassmann, M. Schmied, M. Miyasaka, **K.V. Toyka**, und H.-P. Hartung (1993)
Inhibition of experimental autoimmune encephalomyelitis by antibodies to the intercellular adhesion molecule-1.
Ann. Neurol. 34: 145 - 154
128. P.A. Seeldrayers, J. Syha, S. Morrissey, H. Stodal, K. Vass, S. Jung, H. Lassmann, A. Haase, H.-P. Hartung, **K.V. Toyka** (1993)
NMR investigation of blood-brain damage in adoptive transfer experimental autoimmune encephalomyelitis.
J. Neuroimmunol. 46: 199 - 206
129. Enders, U., H. Karch, **K. V. Toyka**, M. Michels, J.Zielasek, M. Pette, J. Heesemann, H.-P. Hartung (1993)
The spectrum of immune responses to *Campylobacter jejuni* and glyco-conjugates in Guillain-Barré syndrome and in other neurological disorders.
Ann. Neurol. 34: 136 - 144
130. S. Jung, H.-P. Hartung, **K.V. Toyka**
Shared T-cell receptor gene usage in experimental allergic neuritis and encephalomyelitis.
Ann. Neurol. 34: 113 - 114
131. Archelos, J.J., M. Mäurer, S. Jung, **K.V. Toyka**, und H.-P. Hartung (1993)
Suppression of experimental autoimmune neuritis by antibodies to the inter cellular adhesion molecule-1.
Brain 116: 1043 - 1058
132. Pette, M., U. G. Liebert, U. Göbel, H. Grosse-Wilde, H.-P. Hartung, **K. V. Toyka** (1993)
Measles virus-reacted responses of CD4+ T lymphocytes in MS patients and healthy controls.
Neurology 43: 2019 - 2024
133. Hartung, H.-P., M. Michels, K. Reiners, P. Seeldrayers, J. J. Archelos, **K. V. Toyka** (1993)
Soluble ICAM-1 serum levels in multiple sclerosis and viral encephalitis.
Neurology 43: 2331 - 2335
134. Jung, S., I. Huitinga, B. Schmidt, J. Zielasek, C. D. Dijkstra, **K. V. Toyka**, H.-P. Hartung (1993)
Selective elimination of macrophages by dichloromethylene diphosphonate-containing liposomes suppresses experimental autoimmune neuritis.
J. Neurol. Sci. 119: 195 - 202
135. Naumann, M, **K. V. Toyka**, H. H. Goebel, E. Hofmann, H. Reichmann (1993)
Focal myositis of the temporal muscle.
Muscle Nerve, 16: 1374 - 1376
136. Cooke, J. D., H. Hefgter, S. H. Brown, **K.V. Toyka**, H.-J. Freund (1994)
Lambert-Eaton myasthenic syndrome: evaluation of movement performance following drug therapy.
Electromyogr. clin. Neurophysiol. 34, 87 - 93.
137. R. Gold, M. Schmied, G. Giegerich, H. Breitschopf, H.-P. Hartung, **K.V. Toyka**, H. Lassmann (1994)
Differentiation between cellular apoptosis and necrosis by the combined use of in situ tailing and nick translation techniques.
Lab.Invest. 71:219-225

138. Klopstock, T., M. Naumann, B. Schalke, F. Bischof, P. Seibel, M. Kottlors, P. Eckert, K. Reiners, **K. V. Toyka**, H. Reichmann (1994)
Multiple symmetrical lipomatosis: abnormalities in complex IV and a mitochondrial DNA deletion.
Neurology 44:862 - 866
139. Zettl, U. K., R. Gold, H.-P. Hartung, **K. V. Toyka** (1994)
Apoptotic cell death of T-lymphocytes in experimental autoimmune neuritis.
Neurosc. Lett. 176:75 - 79
140. Pfleghaupt, K.-W., Th. Becker, **K. V. Toyka** (1994)
Azetylcholin-Rezeptor-Antikörper in der Diagnostik der Myasthenia gravis: Stichprobenartige Erhebung zur Zuverlässigkeit des Doppelimmun-Präzipitationstests.
Akt. Neurol. 21:63 - 65
141. Pette, M., C. Gengaroli, H.-P. Hartung, A. Greiner, G. Giegerich, **K. V. Toyka** (1994)
Human T lymphocytes distinguish bovine from human P₂ peripheral myelin protein: implications for immunological studies on inflammatory demyelinating neuropathies.
J. Neuroimmunol. 52:47 - 52
142. Zielasek, J., G. Ritter, S. Magi, H.-P. Hartung, **K. V. Toyka** and participating laboratories (1994)
A comparative trial of anti-glycoconjugate antibody assays: IgM antibodies to GM1.
J. Neurol. 241:475-480
143. Kiefer, R., M. L. Supier, **K. V. Toyka**, W. J. Streit (1994)
In situ detection of transforming growth factor-β mRNA in experimental rat glioma and reactive glial cells
Neurosci. Lett., 166: 161 - 164
144. Constable, A. L., P. J. Armati, **K.V. Toyka**, H.-P. Hartung (1994)
Production of prostanoids by Lewis rat Schwann cells in vitro
Brain Res. 635, 75 - 80
145. Pette, M., H.-P. Hartung, **K. V. Toyka** (1994)
Cyclophosphamid in der Therapie der chronisch-progredienten multiplen Sklerose
Nervenarzt 65: 868 - 872
146. Archelos, J. J., M. Mäurer, S. Jung, M. Miyasaka, T. Tamatani, **K. V. Toyka**,
H.-P. Hartung (1994)
Inhibition of experimental autoimmune neuritis by an antibody to the lymphocyte function-associated antigen-1
Lab. Invest. 70,:667 - 675
147. Hartung, H.-P., K. Reiners, M. Michels, R. A. C. Hughes, F. Heidenreich,
J. Zielasek, U. Enders and **K. V. Toyka** (1994)
Serum levels of soluble E-selectin (ELAM-1) in immune-mediated neuropathies.
Neurology 44: 1153-1158
148. Jung, S., **K.V. Toyka** and H.-P. Hartung (1994)
Impact of 15-deoxyspergualin on effector cells in experimental autoimmune diseases of the nervous system in the Lewis rat.
Clin. Exp. Immunol. 98:494-502
149. Pette, M., H.-P. Hartung und **K.V. Toyka** (1994)
Die immunaugmentative Therapie (IAT) als Behandlung der Multiplen Sklerose.
Nervenarzt 65: 878-880

150. Montag, D., K. P. Giese, U. Bartsch, R. Martini, Y. Lang, H. Blüthmann, J. Karthigasan, D. A. Kirschner, E. S. Wintergerst, K.-A. Nave, J. Zielasek, **K. V. Toyka**, H.-P. Lipp and M. Schachner (1994)
Mice deficient for the myelin-associated glycoprotein show subtle abnormalities in myelin.
Neuron 13: 229 - 246
151. Harvey, G. K., **K. V. Toyka**, H.-P. Hartung (1994)
The effects of mast cell degranulation on blood-nerve barrier permeability and nerve conduction in vivo.
J. Neurol. Sci. 125:102-109
152. Jung, S., H.-P. Hartung and **K. V. Toyka** (1994)
Shared T-cell receptor gene usage in experimental allergic neuritis and encephalomyelitis.
Ann. Neurol. 34: 113 - 114.
153. Pette, M., C. Linington, C. Gengaroli, H. Grosse-Wilde, **K. V. Toyka**, H.-P. Hartung (1994)
T lymphocyte recognition sites on peripheral nerve myelin P₀ protein.
J. Neuroimmunol. 54: 29 - 34
154. Zielasek, J., H. Reichmann, H. Künzig, S. Jung, H.-P. Hartung and **K. V. Toyka** (1995)
Inhibition of brain macrophage/microglial respiratory chain enzyme activity in experimental autoimmune encephalomyelitis of the Lewis rat.
Neurosci. Lett. 184:129 - 132
155. Archelos, J. J., M. Mäurer, S. Jung, M. Miyasaka, T. Tamatani, **K. V. Toyka** and H.-P. Hartung (1994)
Inhibition of experimental atuoimmune neuritis by an antibody to the lymphocyte function-associated antigen-1.
Lab. Invest. 70: 667 - 675
156. Müller, B., K. Adelt, H. Reichmann, **K.V. Toyka** (1994)
Atraumatic needle reduces post-lumbar puncture syndrome
J. Neurol. 241:376 - 380
157. Stangel, M., **K.V. Toyka**, H.-P. Hartung, G. giegerich (1994)
Bacterial expression of a soluble T cell receptor alpha chain.
Biochem. Biophys. Res. Comm. 202: 1280-1284x
158. Hartung, H.-P., R. Gold, J. Zielasek, J.J. Archelos, **K.V. Toyka** (1994)
Therapie der akuten Polyradikuloneuritis (Guillain-Barré-Syndrom).
Nervenarzt 65:807-818
159. Jung, S., H.J. Schlüsener, B. Schmidt, A. Fontana, **K.V. Toyka**, H.-P. Hartung (1994)
Therapeutic effect of transforming growth factor- β_2 on actively induced experimental autoimmune neuritis (EAN) but not adoptive transfer EAN
J. Immunol. 83:545-551
160. Pette, M., C. Linington, C. Gengaroli, H. Grosse-Wilde, **K. V. Toyka**, H.-P. Hartung (1994)
T lymphocyte recognition sites on peripheral nerve myelin P₀ protein.
J. Neuroimmunol. 54: 29 - 34
161. Harvey, G.K., **K.V. Toyka**, J. Zielasek, R. Kiefer, C. Simonis, H.-P. Hartung (1995)
Failure of anti-GM1 IgG or IgM to induce conduction block following intraneuronal transfer
Muscle Nerve 18:388 - 394

162. Gold, R., H.-P. Hartung, **K.V. Toyka** (1995)
Therapie mit Immunglobulinen bei neurologischen Autoimmunerkrankungen.
Fortschr. Neurol. Psychiat. 63:17-29
163. Gold, R., G. Giegerich, H.-P. Hartung, **K.V. Toyka** (1995)
T-cell receptor (TCR) usage and apoptosis in Lewis rat experimental autoimmune encephalomyelitis (EAE): Vβ8.2 positive T cells are not essential for induction and course of disease.
Proc. Nat. Acad. Sci. USA 92: 5850 - 5854
164. Lindner, A., G. Becker, M. Warmuth-Metz, B. C. G. Schalke, U. Bogdahn, **K. V. Toyka** (1995)
Magnetic resonance image findings of spinal intramedullary abscess caused by *Candida albicans*: Case report
Neurosurg. 36, 411 - 412
165. Morrissey, S., H. Stodal, U. Zettl, C. Simonis, S. Jung, R. Kiefer, H. Lassmann, H.-P. Hartung, A. Haase, **K.V. Toyka** (1996)
In vivo MRI and ist histological cocorrelates in acute adoptive transfer experimental allergic neuritis:: quantification of inflammation and oedema.
Brain 119: 239 - 248
166. Zettl, U.K., R. Gold, H.-P. Hartung, **K.V. Toyka** (1996)
In situ demonstration of T cell activation and elimination in the peripheral nervous system during experimental autoimmune neuritis in the Lewis rat.
Acta Neuropathol. 91: 360 - 367
167. Zettl, U.K., R. Gold, **K.V. Toyka**, H.-P. Hartung (1995)
Intravenous glucocorticosteroid treatment augments apoptosis in inflammatory T cells in experimental autoimmune neuritis (EAN) of the Lewis rat.
J. Neuropath. Exp. Neurol. 54: 540 - 547
168. Hartung, H.-P., J.J. Archelos, J. Zielasek, R. Gold, M. Koltzenburg, K. Reiners, **K.V. Toyka** (1995)
Circulating adhesion molecules and cytokines in inflammatory demyelination.
Neurology 45: 22 - 32
169. Pette, M., R. Gold, D. Wirth, H.-P. Hartung, **K.V. Toyka** (1995)
Mafosfamide induces DNA fragmentation and apoptosis in human T lymphocytes - a determinant of immunosuppression?
Immunopharmacol. 30: 59 - 69
170. Kiefer, R., W. Streit, **K.V. Toyka**, G.w. Kreutzberg, H.-P. Hartung (1995)
Transforming growth factor - B1: A lesion-associated cytokine of the nervous system.
Int. J. Devel. Neurosci. 13: 331 - 339
171. Archelos, J.J., **K.V. Toyka**, H.-P. Hartung (1995)
B cell responses to the PNS protein PO in experimental autoimmune neuritis.
J. Neurol. Sci. 128:111
172. Harvey, G.K., R. Gold, H.-P. Hartung, **K.V. Toyka** (1995)
Nonneuronal-specific T lymphocytes orchestrate inflammatory peripheral neuropathy
Brain 118: 1263 - 1272
173. Pollard, J., K. W. Westland, G. K. Harvey, S. Jung, J. Bonner, J. M. Spies, **K.V. Toyka**, H. P. Hartung (1995)
Activated T cells of non neural specificity open the blood nerve barrier to circulating antibody.
Ann. Neurol. 37:467 - 475

174. Naumann, M. B. Schalke, Th. Klopstock, H. Reichmann, K. W. Lange, G. Wiesbeck, **K. V. Toyka**, K. Reiners (1995)
Neurological multisystem manifestation in Multiple symmetric Lipomatosis
Muscle Nerve 18: 693 - 698
175. Lindner, A. Ch. Schneider, K. M. Hasert, N. Soerensen, **K. V. Toyka** (1995)
Isolated meningeal tuberculoma mimicking meningioma.
Surg. Neurol. 43: 81 - 84
176. Zielasek, J., R. Martini, **K. V. Toyka** (1996)
The functional disorder of P₀ gene mutations.
Muscle Nerve (in press)
177. Gold, R., **K. V. Toyka**, H.-P. Hartung (1995)
Synergistic effect of gamma-IFN and TNF- α on expression of immune molecules and antigen presentation by Schwann cells.
Cell Immunol. 165: 65 - 70
178. Hartung, H.-P., K. Reiners, J.J. Archelos, J. Zielasek, F. Heidenreich, K. Pflughaupt and **K.V. Toyka** (1995)
Circulating adhesion molecules and TNF receptor (60 kDa) in Multiple Sclerosis: Correlation with MRI and comparison with viral encephalitis.
Ann. Neurol. 38: 186 - 193
179. Zielasek, J., S. Jung, R. Gold, F. Y. Liew, **K.V. Toyka**, and H. P. Hartung (1995)
Administration of nitric oxide synthase inhibitors in experimental autoimmune neuritis and experimental autoimmune encephalomyelitis.
J. Neuroimmunol. 58: 81 - 88
180. Bufler, J., S. Kahlert, S. Tzartos, A. Maelicke, **K.V. Toyka**, C. Franke (1996)
Activation on blockade of mouse muscle nicotinic channels by antibodies directed against the binding site of the acetylcholine receptor.
J. Physiol. 492.1: 107 - 114
181. Gold, R., E. R. Baumgartner, B. Fowler, U. Bogdahn, U. Wendel, L. Kappos, **K. V. Toyka** (1996)
Hereditary defect of cobalamin metabolism (homocystinuria and methylmalonic aciduria) of juvenile onset with remitting myeloneuropathy.
J. Neurol. Neurosurg. Psychiatr. 60: 107 - 108
182. Adelkofer, K., R. Martini, A. Aguzzi, J. Zielasek, **K.V. Toyka**, U. Suter (1995)
Hypermyelination and demyelinating peripheral neuropathy in Pmp22-deficient mice
Nature Genetics 11: 274 - 280 (with Editorial)
183. Martini, R., J. Zielasek, **K.V. Toyka**, K. P. Giese, M. Schachner (1995)
Protein zero (PO)-deficient mice show myelin degeneration in peripheral nerves characteristic of inherited human neuropathies
Nature Genetics 11: 281 - 285 (with Editorial)
184. Reichmann, H., B. Schalke, P. Seibel, M. Naumann, **K.V. Toyka** (1995)
Sarcoid Myopathy and mitochondrial respiratory chain defects: clinicopathological, biochemical and molecular biological analyses
Neuromusc. Disord. 5: 577 - 283
185. Jung, S., **K.V. Toyka**, H.-P. Hartung (1995)
Suppression of experimental autoimmune encephalomyelitis in Lewis rats by antibodies against CD2
Eur. J. Immunol. 25: 1391 - 1398

186. Giegerich, G., M. Stangel, N. Torres-Nagel, T. Hünig, **K.V. Toyka** (1995)
Sequence and diversity of rat T-cell receptor Tcra V8 gene segments
Immunogenetics 42: 304 - 305
187. Schmidt, B., **K.V. Toyka**, R. Kiefer, J. Full, H.-P. Hartung, J. Pollard (1996)
Inflammatory infiltrates in sural nerve biopsies in Guillain-Barré Syndrome and
chronic inflammatory demyelinating neuropathy
Muscle Nerve 19: 474 - 487
188. Weishaupt, A., G. Giegerich, S. Jung, R. Gold, U. Enders, M. Pette, K. Hayasaka,
H.-P. Hartung, **K.V. Toyka** (1996)
T-cell antigenic and neuritogenic activity of recombinant human peripheral myelin
P2 protein
J. Neuroimmunol. 63: 149 - 156
189. Airaksinen, M.S., M. Koltzenburg, G.R. Lewin, Y. Masu, C. Helbig, E. Wolf,
G. Brem, **K.V. Toyka**, H. Thoenen, M. Meyer (1996)
Specific sub-types of cutaneous mechanoreceptors require neurotrophin-3 following
peripheral innervation
Neuron 16: 287 - 295
190. Stangel, M., U.K. Zettl, E. Mix, J. Zielasek, **K.V. Toyka**, H.-P. Hartung, R. Gold
(1996)
H₂O₂ an nitric oxide-mediated oxidative stress induce apoptosis in rat skeletal
muscle myoblasts
J. Neuropath. Exp. Neurol. 55: 36 - 43
191. Buchwald, B. A. Weishaupt, **K.V. Toyka**, J. Dudel (1995)
Immunoglobulin G from a patient with Miller-Fisher syndrome rapidly and reversibly
depresses evoked quantal release at the neuromuscular junction of mice
Neurosci. Lett. 201: 263 - 166
192. Gold, R. M. Schmied, U. Tontsch, H.-P. Hartung, H. Wekerle, **K.V. Toyka**,
H. Lassmann (1996)
Antigen presentation by astrocytes primes rat T lymphocytes for apoptotic cell death:
a model for T cell apoptosis *in vivo*
Brain 119: 651 - 659
193. Gold, R., J. Zielasek, J.M. Schröder, J. Cedarbaum, H.-P. Hartung, M. Sendtner,
K.V. Toyka (1996)
Treatment with ciliary neurotrophic factor (CNTF) does not improve regeneration in
experimental autoimmune neuritis (EAN) of the Lewis rat
Muscle Nerve (in press)
194. Gold, R., J. Zielasek, R. Kiefer, **K.V. Toyka**, H.-P. Hartung (1996)
Secretion of nitrite by Schwann cells and its effect on T cell activation *in vitro*
Cell Immunol. 168: 69 - 77
195. Lindner, A., K. Reiners, **K.V. Toyka** (1996)
Meningeal hyperfusion visualized by MRI in a patient with visual hallucinations and
migraine
Headache 36: 53 - 57
196. Naumann M, H. Reichmann, H. H. Goebel, C. Moll, **K. V. Toyka** (1996)
Glucocorticoid-sensitive hereditary inclusion body myositis
J. Neurol. 243: 126 - 130

197. Kiefer, R., K. Funa, T. Schweitzer, S. Jung, O. Bourde, **K. V. Toyka**, H.-P. Hartung (1996)
Transforming growth factor- β 1 in experimental autoimmune neuritis
Am. J. Pathol. 148: 211 - 223
198. Zettl, U. K., R. Gold, **K. V. Toyka**, H.-P. Hartung (1996)
In situ demonstration of T cell activation and elimination in the peripheral nervous system
during experimental autoimmune neuritis in the Lewis rat
Acta Neuropathol. 91: 360 - 367
199. Jung, S., **K. V. Toyka**, H.-P. Hartung (1995)
Soluble complement receptor type 1 inhibits experimental autoimmune neuritis in Lewis rat
Neurosci. Lett. 200: 167 - 170
200. Marx, A., A. Wilisch, A. Schultz, A. Greiner, B. Magi, V. Pallini, B. Schalke, **K. V. Toyka**, W. Nix, T. Kirchner, H.-K. Müller-Hermelink (1996)
Expression of neurofilaments and of a titin epitope in thymic epithelial tumors
Am. J. Pathol. 148: 1839 - 1859
201. Lindner, A., G. Becker, M. Warmuth-Metz, B. C. G. Schalke, U. Bogdahn, **K. V. Toyka** (1995)
Magnetic resonance image findings of spinal intramedullary abscess caused by candida albicans:
case report
Neurosurgery 36: 411 - 412
202. Naumann, M., G. Becker, **K. V. Toyka**, T. Supprian, K. Reiners (1996)
Lenticular nucleus lesion in idiopathic dystonia detected by transcranial sonography
Neurology (in press)
203. Becker, G., M. Naumann, M. Scheubeck, E. Hofmann, M. Deimling, A. Lindner, G. Gahn, C. Reiners, **K. V. Toyka**, K. Reiners (1996)
Comparison of transcranial sonography, MRI and SPECT findings in idiopathic spasmodic torticollis
Movement Disorders (in press)
204. Jung, S., J. Zielasek, G. Köllner, T. Donhauser, **K. V. Toyka**, H.-P. Hartung (1996)
Preventive but not therapeutic application of rolipram ameliorates experimental autoimmune encephalomyelitis in Lewis rats
J. Neuroimmunol. (in press)